|Table of Contents|

Research progress on the mode and clinical significance of BRAF mutation and co-mutation in non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 21
Page:
4205-4212
Research Field:
Publishing date:

Info

Title:
Research progress on the mode and clinical significance of BRAF mutation and co-mutation in non-small cell lung cancer
Author(s):
LI Lanlan; HUANG Jian
The Center of Pathological Diagnosis and Research,Affliated Hospital of Guangdong Medical University,Guangdong Zhanjiang 524001,China.
Keywords:
non-small cell lung cancer; BRAF gene; molecular characteristics; co-mutation; drug resistance
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.21.035
Abstract:
Mouse sarcoma virus oncogene homologue B1(v-raf murine sarcoma viral oncogene homolog B1,BRAF) gene is one of the important driving genes of non-small cell lung cancer(NSCLC).Mastering the structure,function and mutation mechanism of BRAF protein is the basis of NSCLC targeted therapy for BRAF mutation.The drug resistance of targeted treatment of BRAF mutant lung cancer is the biggest challenge in the process of treatment.Studies have found that BRAF can not only induce lung cancer through single gene mutation,but also co-mutate with other common driving genes(such as EGFR,KRAS,ALK,etc.),and may become an important way for NSCLC to target drug resistance.Therefore,this article will review the molecular and clinical characteristics of BRAF mutation and its co-mutation with other genes,so as to provide theoretical basis and possible treatment strategies for further study of the mechanism of drug resistance in BRAF targeted therapy.

References:

[1]FREDDIE,BRAY,MATHIEU,LAVERSANNE,et al.Global cancerstatistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
[2] HERBST ROY S,MORGENSZTERN DANIEL,BOSHOFF CHRIS.The biology and management of non-small cell lung cancer［J］.Nature,2018,553(7689):446-454.
[3] PAMELA MP,PAUL SM.A genome-based strategy uncovers frequent BRAF mutations in melanoma［J］.Cancer Cell,2002,2(1):5-7.
[4]CLAUDIA WELLBROCK,MARIA KARASARIDES,MARAIS RICHARD,et al.The RAF proteins take centre stage［J］.Nat Rev Mol Cell Biol,2004,5(11):875-885.
[5] MERCER KATHRYN E,PRITCHARD CATRIN A.Raf proteins and cancer:B-Raf is identified as a mutational target［J］.Biochim Biophys Acta,2003,1653:25-40.
[6] ASCIERTO PAOLO A,KIRKWOOD JOHN M,GROB JEAN-JACQUES,et al.The role of BRAF V600 mutation in melanoma［J］.J Transl Med,2012,10:85.
[7] WEISS RE,REFETOFF S.Genetic diagnosis of endocrine disorders［M］.Waltham,MA:Academic Press,2010:117-138.
[8] ZHAN YAO,RONA YAEGER,RODRIK-OUTMEZGUINE VANESSA S,et al.Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS［J］.Nature,2017,548(7666):234-238.
[9] DAGOGO-JACK IBIAYI,MARTINEZ PABLO,YEAP BEOW Y,et al.Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer［J］.Clini Cancer Res,2019,25(1):158-165.
[10] QUAN LIN,HAORAN ZHANG,DING HUAXIN,et al.The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients［J］.J Transl Med,2019,17(1):298-308.
[11] ZHAN YAO,NEILAWATTIE M.TORRES,TAO ANTHONY,et al.BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition［J］.Cancer Cell,2015,28(3):370-383.
[12] GARNETT MATHEW J,MARAIS RICHARD.Guilty as charged:B-RAF is a human oncogene［J］.Cancer Cell,2004,6(4):313-319.
[13] SUZANNE,KAZANDJIAN,EMMANUELLE,et al.The clinical,genomic,and transcriptomic landscape of BRAF mutant cancers［J］.Cancers(Basel),2024,16(2):445.
[14] ANDREA,AMBROSINI-SPALTRO,CLAUDIA,et al.Clinicopathological features of non-small cell lung carcinoma with BRAF mutation［J］.Curr Oncol,2023,30(11):10019-10032.
[15] ROSSANA,RUIZ,MARCO,et al.Genomic landscape of lung cancer in the young［J］ Front Oncol,2022,12:910117.
[16] GUAN HUI TRICIA,LIM,KEVIN JON,et al.Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort［J］.Ling Cancer,2022,173:71-74.
[17] PERRONE FABIANA,MAZZASCHI GIULIA,MINARI ROBERTA.BRAF multicenter observational study on metastatic non-small cell lung cancer harboring mutations:Focus on clinical characteristics and treatment outcome of V600E and non-V600E subgroups［J］.Cancers(Basel),2022,14(8):2019.
[18] MAMTA,GURAV,SRIDHAR,et al.Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience［J］.J Cancer Res Clin,2023,149(10):7413-7425.
[19] ASHLEY,GARCIA,MARIA DEL MAR,et al.Assessment of BRAF V600E(VE1) immunochemistry for the detection of BRAF V600E mutation in non-small cell lung carcinoma cytology specimens［J］.Cancer Cytopathol,2023,131(1):50-57.
[20] DAVID PLANCHARD,TAE MIN KIM,MAZIERES JULIEN,et al.Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer:a single-arm,multicentre,open-label,phase 2 trial［J］.Lancet Oncol,2016,17(5):642-650.
[21] EVGENY N,IMYANITOV,NATALIA V,et al.Pathways and targeting avenues of BRAF in non-small cell lung cancer［J］.Expert Opin Ther Tar,2024,28(7):613-622.
[22]LAN,JIANG,PIRONG,et al.BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC:a case report［J］.J Cancer Res Clin,2024,150(3):162.
[23] AKIKO,TAMURA,RYOKO,et al.Response to dabrafenib plus trametinib on a rare BRAF mutation(V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient［J］.Thorac Cancer,2024,15(18):1454-1456.
[24] MATTHEW S,LARA,COLLIN M,et al.Targeting MEK in non-small cell lung cancer［J］.Curr Prob Cancer,2024,49:101065.
[25] WARREN FISKUS,NICHOLAS MITSIADES.B-Raf inhibition in the clinic:Present and future［J］.Annu Rev Med,2016,67:29-34.
[26] MU YUXIN,YANG KE,HAO XUEZHI,et al.Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer［J］.Front Oncol,2020,10:603.
[27] DAVID PLANCHARD,BENJAMIN BESSE,GROEN HARRY JM,et al.Dabrafenib plus trametinib in patients with previously treated BRAF V600E-mutant metastatic non-small cell lung cancer:an open-label,multicentre phase 2 trial［J］.Lancet Oncol,2016,17(7):1307-1316.
[28] GREGORY J,RIELY,EGBERT F,et al.Erratum:Phase II,open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer［J］.J Clin Oncol,2024,42(2):245.
[29] GREGORY J,RIELY,EGBERT F,et al.A plain language summary of the PHAROS study:the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer［J］.Future Oncol,2024,20(16):1047-1055.
[30] FRED R HIRSCH,GIORGIO V SCAGLIOTTI,KWON REGINA,et al.Lung cancer:current therapies and new targeted treatments［J］.Lancet,2017,389(10066):299-311.
[31] WANG HW,CHENG L,ZHAO C.Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring mutations.［J］.Transl Lung Cancer Res,2023,12:219-229.
[32] ZHAO L,WANG L,JIA XM,et al.The coexistence of genetic mutations in thyroid carcinoma predicts histopathological factors associated with a poor prognosis:A systematic review and network Meta-analysis［J］.Front Oncol,2020,10:540238.
[33] GUTIEERREZ-CASTANEDA LUZ D,GAMBOA MAURICIO,NOVA JOHN A,et al.Mutations in the BRAF,NRAS,and C-KIT genes of patients diagnosed with melanoma in colombia population［J］.Biomed Res Int,2020,2020:2046947.
[34] JAUHRI MAYANK,BHATNAGAR AKANKSHA,GUPTA SATISH,et al.Prevalence and coexistence of KRAS,BRAF,PIK3CA,NRAS,TP53,and APC mutations in Indian colorectal cancer patients:Next-generation sequencing-based cohort study［J］.Tumour Biol,2017,39(2):871-876.
[35] CARDARELLA S,OGINO A,NISHINO M,et al.Clinical,pathologic,and biologic features associated with BRAF mutations in non-small cell lung cancer［J］.Clin Cancer Res,2013,19:4532-4540.
[36] ANYA M.LITVAK,PAUL K.PAIK,WOO KAITLIN M,et al.Clinical characteristics and course of 63 patients with BRAF mutant lung cancers［J］.J Thorac Oncol,2014,9(11):1669-1674.
[37] BRUSTUGUN OT,KHATTAK AM,TROMBORG AK,et al.BRAF-mutations in non-small cell lung cancer［J］.Lung Cancer,2014,84:36-38.
[38] KINNO T,TSUTA K,SHIRAISHI K,et al.Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations［J］.Ann Oncol,2014,25:138-142.
[39] LIZA C.VILLARUZ MD,MARK A,ABBERBOCK SHIRA,et al.Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the lung cancer mutation consortium［J］.Cancer,2015,121(3):448-456.
[40] MARTIN MARTORELL PALOMA,HUERTA MARISOL,COMPAN QUILIS AMPARO,et al.Coexistence of EGFR,KRAS,BRAF,and PIK3CA mutations and ALK rearrangement in a comprehensive cohort of 326 consecutive Spanish non-squamous NSCLC patients［J］.Clin Lung Cancer,2017,18:e395-e402.
[41] SALIMIAN KJ,FAZELI R,ZHENG G,et al.V600E BRAF versus non-V600E BRAF mutated lung adenocarcinomas:cytomorphology,histology,coexistence of other driver mutations and patient characteristics［J］.Acta Cytol,2018,62:79-84.
[42] AULIAC JB,BAYLE S,VERGNENEGRE A,et al.Patients with non-small-cell lung cancer harbouring a mutation:a multicentre study exploring clinical characteristics,management,and outcomes in a real-life setting:EXPLORE GFPC 02-14［J］.Curr Oncol,2018,25:e398-e402.
[43] ZHUANG XB,ZHAO C,LI JY,et al.Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR,ALK,ROS1,KRAS or BRAF［J］.Cancer Med,2019,8:2858-2866.
[44] MA YUHUI,LI QUAN,DU YAXI,et al.Oncogenic genetic alterations in non-small-cell lung cancer(NSCLC) in southwestern China［J］.Cancer Manag Res,2020,12:10861-10874.
[45] JINGJING QU,QIAN SHEN,YUPING LI,et al.Clinical characteristics,co-mutations,and treatment outcomes in advanced non-small-cell lung cancer patients with the BRAF-V600E mutation［J］.Front Oncol,2022,12:911303.
[46] TISSOT C,COURAUD S,TANGUY R,et al.Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations［J］.Lung Cancer,2016,91:23-28.
[47] KIM SUNG-MOO,KIM HWAN,JANG KANG WON,et al.EGFR-mediated reactivation of MAPK signaling induces acquired resistance to GSK2118436 in BRAF V600E mutant NSCLC cell lines［J］.Mol Cancer Ther,2016,15(7):1627-1636.
[48] LIN LUPING,ASTHANA SAURABH,CHAN ELTON,et al.Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.Proceedings of the National Academy of Sciences of the United States of America［J］.Proc Natl Acad Sci USA,2014,111:E748-757.
[49] HO CHAO-CHI,LIAO WEI-YU,LIN CHIH-AN,et al.Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib［J］.J Thorac Oncol,2017,12:567-572.
[50] MINARI ROBERTA,BORDI PAOLA,LA MONICA SILVIA,et al.Concurrent acquired BRAF V600E mutation and MET amplification as resistance mechanism of first-line osimertinib treatment in a patient with EGFR-mutated NSCLC［J］.J Thorac Oncol,2018,13:e89-e91.
[51] MENG PEI,KOOPMAN BART,KOK KLAAS,et al.Combined osimertinib,dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation［J］.Lung Cancer,2020,146:358-361.
[52] VOJNIC M,KUBOTA D,KURZATKOWSKI C,et al.Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers［J］.J Thorac Oncol,2019,14:802-815.
[53] DAGOGO-JACK IBIAYI,PIOTROWSKA ZOFIA,COBB ROSEMARY,et al.Response to the combination of osimertinib and trametinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF fusion［J］.J Thorac Oncol,2019,14:226-228.
[54] CLINT TAONAISHE,CHIMBANGU,ZHOU YA,et al.Promising response of dabrafenib,trametinib,and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations［J］.Anti-Cancer Drug，2024,35(1):109-115.
[55]CORRADO,ORCIUOLO,FEDERICO,et al.Pretreated EGFR(del19)/BRAF(V600E) lung adenocarcinoma with leptomeningeal disease achieving long-lasting disease control on osimertinib,dabrafenib,and trametinib:A case report［J］.JTO Clin Res Rep,2023,4(8):100545.
[56] HAN WU,JIAN FENG,SHUN LU.A large-scale,multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.［J］.Cancer Med,2024,13(10):e7305.
[57] RAJAGOPALAN HARITH,BARDELLI ALBERTO,LENGAUER CHRISTOPH,et al.Tumorigenesis:RAF/RAS oncogenes and mismatch-repair status［J］.Nature,2002,418:934.
[58] PASQUALE PISAPIA,FRANCESCO PEPE,MALAPELLE UMBERTO,et al.BRAF mutations in lung cancer［J］.Acta Cytol,2019,63(3):247-250.
[59] BRACHT JILLIAN WILHELMINA PAULINA,KARACHALIOU NIKI,BIVONA TREVER,et al.BRAF mutations classes I,II,and III in NSCLC patients included in the SLLIP trial:The need for a new pre-clinical treatment rationale［J］.Cancers,2019,11(9):1381-1394.
[60] BOURHIS AMELIE,REMOUE ANNABELLE,UGUEN ARNAUD,et al.KRAS and BRAF double mutations and functional classes of BRAF mutations in non-small-cell lung cancers［J］.Clin Lung Cancer,2020,21:e240-e242.
[61] RACHEL J,KEOGH,MARTIN P,et al.Genomic landscape of NSCLC in the republic of Ireland［J］.JTO Clin Res Rep,2024,5(2):100627.
[62] LA MS,MINARI R,CRETELLA D,et al.Acquired BRAF G469A mutation as a resistance mechanism to first-line osimertinib treatment in NSCLC cell lines harboring an EGFR exon 19 deletion［J］.Target Oncol,2019,14:619-626.
[63] RUDIN CHARLES M,HONG KELVIN,STREIT MICHAEL,et al.Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer［J］.J Thorac Oncol,2013,8:e41-42.
[64] FACCHINETTI FRANCESCO,LACROIX LUDOVIC,MEZQUITA LAURA,et al.Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer［J］.Eur J Cancer,2020,132:211-223.
[65] NIEMANTSVERDRIET M,SCHUURING E,ELST AT,et al.KRAS mutation as a resistance mechanism to BRAF/MEK inhibition in NSCLC［J］.J Thorac Oncol,2018,13(12):249-251.
[66]HALLIN JILL,ENGSTROM LARS D,HARGIS LAUREN,et al.The KRAS inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients［J］.Cancer Discov,2020,10:54-71.
[67] OSTREM JONATHAN M,PETERS ULF,SOS MARTIN L,et al.K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions［J］.Nature,2013,503:5485-5451.
[68]KARATRASOGLOU EA,CHATZIANDREOU ILENIA,SAKELLARIOU STRATIGOULA,et al.Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients:correlation with clinical data［J］.Virchows Arch,2020,477:207-217.
[69] SONG PENG,YANG DONGLIANG,WANG HANPING,et al.Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients［J］.Thorac Cancer,2020,11:1647-1654.
[70] SODA MANABU,CHOI YOUNG LIM,ENOMOTO MUNEHIRO,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer［J］.Nature,2007,448:561-566.
[71] LIN JESSICA J,RIELY GREGORY J,SHAW ALICE T,et al.Targeting ALK:Precision medicine takes on drug resistance［J］.Cancer Discov,2017,7:137-155.
[72]AIKO,OGIMOTO,NAOKO,et al.HIP1-ALK-rearranged lung cancer in a young adult with BRAF V600E mutation detected after ALK tyrosine kinase inhibitor therapy:A case report［J］.JTO Clin Res Rep,2024,5(1):100612.
[73]THOMAS,WAUTERS ELS,WAUTERS ISABELLE.Case report:BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma［J］.Front Oncol,2022,12:985446.
[74] SHI RUOSHI,FILHO SEBASTIAO N MARTINS,LI MING,et al.BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase(ALK) inhibitor alectinib in lung cancer［J］.Lung Cancer,2020,146:78-85.

Memo

Memo:
-
Last Update: 2024-09-30